Treatment with A1155463 reduced senescence markers in DM1 myoblasts (e.g., number of SA‐β‐galactosidase positive cells, P16 expression) as well as SASP expression (e.g., reduced levels of CSF3, CXCL1, CXCL8, CCL2, MMP‐1, and MMP‐3) [37]. The gene discussed is CXCL1; the disease is myotonic dystrophy type 1.